Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 1 Trials for Fludarabine (DB01073)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03326921HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantTreatment